Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment

Purpose of review To investigate the JZE alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. Recent findings JZE was found to be significantly extended in patients with endometriosis, leading to the conclusion that endometriosis is a primary disease of the uterus, much like adenomyosis. Statistical correlation was then demonstrated between the severity of endometriosis and the depth of the adenomyosis infiltrates, hence the thickening of the JZE. Stem cells, predominantly found in the JZE were also found in histological sections of leiomyoma, suggested to be the origin of leiomyoma. This reservoir of JZE stem cells is influenced by different stressors leading to their differentiation into leiomyoma, endometriosis, adenomyosis or endometrial cancer, according to the stressor. The variability in presentation was hypothesized to be connected to genetic and epigenetic factors. JZE was also suggested to act as a barrier, stopping endometrial carcinoma cells invasion and metastasis. In addition, JZE plays a major role in conception, pregnancy and postpartum. Summary JZE is an important anatomical landmark of the uterus contributing to normal uterine function under the influence of ovarian hormones. Alterations of the JZE thickness and contractility can be used as pathognomonic clinical markers in infertility and chronic pelvic pain, for subendometrial and myometrial disorders, for example, adenomyosis and fibroids. Prospe...
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: WOMEN'S HEALTH: Edited by Joseph Aquilina Source Type: research

Related Links:

Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundUntil now, there is no clear conclusion on the relationship between the surgical margin status after radical prostatectomy (RP) and prostate cancer-specific mortality (PCSM). Therefore, we conducted this systematic review and meta-analysis based on all eligible case –control studies.MethodsA systematic and comprehensive literature search was performed based on PUBMED and EMBASE to identify all of the potentially relevant publications which were published before September 2019. Hazard ratio (HR) for PCSM was independently extracted by two reviewers from all eligible studies. Pooled HR estimates with ...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeTo identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).Methods/PatientsWe explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs  ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.ResultsNLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069,p = 0.0034,p = 0.0160,p = 0.0063;p 
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn conclusion, both the venous access catheter selection algorithm and the proposed recommendations aim to respond to the needs revealed in clinical practice and to become an integrable tool in electronic prescription systems to offer homogeneous criteria for action in cancer patients that require venous access, optimizing the use of available health resources with the highest safety and quality of life for the patient.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
ConclusionmiR-1976 may serve as a promising non-invasive biomarker for the diagnosis of BC in the future.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
AbstractIn this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Espa ñola de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination ofKRAS,NRAS andBRAF mutations and the convenience of determining the amplification of human epidermal growth factor ...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Expect another 30 to 40 years of increasing numbers of HPV-related oropharynx cancers, said an expert.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
CONCLUSION: The 2010 SPILF-AFSSAPS guiding criteria for Streptococcus pneumoniae CAP are found in very variable proportions and do not, in their current form, make it possible to accurately guide towards a pneumococcal etiology in patients included in the PACSCAN study. PMID: 32950610 [PubMed - as supplied by publisher]
Source: Medecine et Maladies Infectieuses - Category: Infectious Diseases Tags: Med Mal Infect Source Type: research
Authors: MacDonald-Ramos K, Michán L, Martínez-Ibarra A, Cerbón M Abstract Silymarin is obtained from the Milk thistle plant Silybum marianum and has been used over the centuries to treat principally liver disease, although it has also been studied for its beneficial effects in cardioprotection, neuroprotection, immune modulation, and cancer among others. Importantly, silymarin's active component silybin is a flavonolignan that exhibits different activities such as; scavenger, anti-oxidant, anti-inflammatory, and recently revealed, insulin-sensitizing properties which have been explored in clin...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Chronic Pain | Endometrial Cancer | Endometriosis | Genetics | Hormones | Infertility | Leiomyoma | OBGYN | Ovarian Cancer | Ovaries | Pain | Pregnancy | Reproduction Medicine | Statistics | Stem Cell Therapy | Stem Cells | Women